**Specifications Table**TableSubject area*Medicine*More specific subject area*Epidemiology*Type of data*Tables*How data was acquired*Unprocessed primary data*Data format*Analyzed*Experimental factors*Duplicates were deleted from the dataset*Experimental features*The unprocessed data of the Cancer Registry were provided by the Health Monitoring Unit of the Ministry of Health of the Republic of Cyprus in an electronic form and were analyzed using STATA version 14 (StataCorp LP, College Station, Texas, USA)*Data source location*Republic of Cyprus*Data accessibility*Data are provided within this article*

**Value of the data**•The presented data can be used as reference for the Republic of Cyprus for the years 2005--2013 and can be compared with those of other studies that might be published in the future.•The data can be included in analyses to better understand the epidemiology of breast cancer.•The data can be used for developing policies related to breast cancer prevention.

1. Data {#s0005}
=======

This article includes analyzed data on breast cancer cases obtained from the Cyprus Cancer Registry in the Health Monitoring Unit of the Ministry of Health of the Republic of Cyprus for the period 2005--2013. Demographic and clinical/histological parameters of newly diagnosed breast cancer cases are shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}. [Table 6](#t0030){ref-type="table"} presents the classification of histological types and their subtypes (always as primary sites) used for the analysis of data. Breast cancer mortality per year can be found in [Table 7](#t0035){ref-type="table"}. Net survival rates for breast cancer ([Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"}) are presented for 2004--2008 and 2009--2013.Table 1Demographic characteristics of newly diagnosed breast cancer cases (*N* = 4769) by year of diagnosis (2005--2013).Table 1**200520062007200820092010201120122013TotalGender** \[*N* (%)\]Female452(98.9)433(98.2)535(98.9)510(98.5)476(99.2)549(99.5)602(99.2)562(99.1)603(99.5)4722(99.0)Male5(1.1)8(1.8)6(1.1)8(1.5)4(0.8)3(0.5)5(0.8)5(0.9)3(0.5)47(1.0)**Age**Median (IQR)57(46--67)58(47--68)58(48--68)58(49--69)58(49--68)58(49--69)59(49--68)61(49--69)60(50--69)59(49--59)                                            **Ethnicity** \[*N* (%)\]Greek-Cypriot398(87.1)372(84.4)460(85.0)435(84.0)411(85.6)467(84.6)508(83.7)475(83.8)524(86.5)4050(85.0)Non-Greek-Cypriot[a](#tbl1fna){ref-type="table-fn"}59(12.9)65(14.7)76(14.1)77(14.9)65(13.6)81(14.7)83(13.7)73(12.9)71(11.7)650(13.6)Unknown0(0.0)4(0.9)5(0.9)6(1.1)4(0.8)4(0.7)16(2.6)19(3.3)11(1.8)69(1.4)                                            **Marital Status** \[*N* (%)\]Single31(6.8)23(5.2)28(5.2)26(5.0)26(5.4)30(5.4)38(6.3)34(6.0)31(5.1)267(5.6)Married307(67.2)298(67.6)383(70.8)369(71.3)348(72.5)383(69.4)410(67.5)361(63.7)399(65.9)3258(68.3)Divorced/Separated22(4.8)32(7.2)34(6.3)25(4.8)21(4.4)27(4.9)32(5.3)43(7.6)36(5.9)272(5.7)Widowed57(12.5)59(13.4)61(11.3)57(11.0)46(9.6)62(11.2)66(10.9)64(11.3)60(9.9)532(11.2)Unknown40(8.7)29(6.6)35(6.4)41(7.9)39(8.1)50(9.1)61(10.0)65(11.4)80(13.2)440(9.2)                                            **Smoking History** \[*N* (%)\]Yes45(9.8)54(12.2)82(15.2)60(11.6)34(7.1)65(11.8)80(13.2)83(14.6)59(9.7)562(11.8)No164(35.9)137(31.1)188(34.7)213(41.1)214(44.6)243(44.0)259(42.7)247(43.6)241(39.8)1906(40.0)Unknown248(54.3)250(56.7)271(50.1)245(47.3)232(48.3)244(44.2)268(44.1)237(41.8)306(50.5)2301(48.2)                                            **Birthplace**[b](#tbl1fnb){ref-type="table-fn"} \[*N* (%)\]Ammochostos71(15.5)57(12.9)92(17.0)61(11.8)92(19.2)66(12.0)94(15.5)76(13.4)92(15.2)701(14.7)Kyrenia18(3.9)16(3.6)34(6.3)12(2.3)13(2.7)20(3.6)20(3.3)18(3.2)19(3.1)170(3.6)Larnaca43(9.4)32(7.3)43(8.0)30(5.8)37(7.7)35(6.3)42(6.9)45(7.9)50(8.3)357(7.5)Nicosia118(25.8)130(29.5)143(26.4)157(30.3)147(30.6)174(31.5)173(28.5)177(31.2)200(33.0)1419(29.8)Limassol66(14.4)56(12.7)79(14.6)81(15.6)59(12.3)68(12.3)83(13.7)72(12.7)72(11.9)636(13.3)Pafos35(7.7)33(7.5)30(5.6)36(7.0)27(5.6)47(8.5)42(6.9)27(4.8)31(5.1)308(6.5)Unknown106(23.3)117(26.5)120(22.1)141(27.2)105(21.9)142(25.8)153(25.2)152(26.8)142(23.4)1178(24.6)[^1][^2]Table 2Cancer grade of newly diagnosed breast cancer cases (*N* = 4700) by ethnicity and year of diagnosis (2005--2013).Table 2**Cancer grade200520062007200820092010201120122013TotalGreek-Cypriot** \[*N* (%)\]I; Well Differentiated32(8.0)36(9.7)59(12.8)33(7.6)35(8.5)36(7.7)28(5.5)38(8.0)30(5.7)327(8.1)II; Moderately Differentiated181(45.5)161(43.3)200(43.5)173(39.8)182(44.3)205(43.9)236(46.5)209(44.0)264(50.4)1811(44.7)III; Poorly Differentiated97(24.4)98(26.3)110(23.9)159(36.5)135(32.8)144(30.8)160(31.5)163(34.3)143(27.3)1209(29.8)Undifferentiated/Unknown88(22.1)77(20.7)91(19.8)70(16.1)59(14.4)82(17.6)84(16.5)65(13.7)87(16.6)703(17.4)                                            **Non-Greek- Cypriot**[a](#tbl2fna){ref-type="table-fn"} \[*N* (%)\]I; Well Differentiated3(5.1)3(4.6)2(2.6)5(6.4)2(3.1)4(4.9)1(1.2)4(5.5)3(4.2)27(4.2)II; Moderately Differentiated30(50.9)25(38.5)29(38.2)32(41.6)28(43.1)38(46.9)41(49.4)30(41.1)29(40.8)282(43.4)III; Poorly Differentiated11(18.6)23(35.4)26(34.2)32(41.6)30(46.1)27(33.4)33(39.8)30(41.1)33(46.5)245(37.7)Undifferentiated/Unknown15(25.4)14(21.5)19(25.0)8(10.4)5(7.7)12(14.8)8(9.6)9(12.3)6(8.5)96(14.7)                                            **Total** \[*N* (%)\]I; Well Differentiated35(7.7)39(8.9)61(11.4)38(7.4)37(7.8)40(7.3)29(4.9)42(7.7)33(5.6)354(7.5)II; Moderately Differentiated211(46.2)186(42.6)229(42.7)205(40.0)210(44.1)243(44.2)277(46.9)239(43.5)293(49.2)2093(44.5)III; Poorly Differentiated108(23.6)121(27.7)136(25.4)191(37.4)165(34.7)171(31.3)193(32.6)193(35.3)176(29.6)1454(30.9)Undifferentiated/Unknown103(22.5)91(20.8)110(20.5)78(15.2)64(13.4)94(17.2)92(15.6)74(13.5)93(15.6)799(17.0)[^3]Table 3Cancer behaviour of newly diagnosed breast cancer cases (*N* = 4700) by ethnicity and year of diagnosis (2005--2013).Table 3**Cancer behaviour200520062007200820092010201120122013TotalGreek-Cypriot** \[*N* (%)\]In situ33(8.3)19(5.1)48(10.4)42(9.7)39(9.5)43(9.2)47(9.2)38(8.0)57(10.9)366(9.0)Invasive365(91.7)353(94.9)412(89.6)393(90.3)372(90.5)424(90.8)461(90.8)437(92.0)468(89.1)3685(91.0)                                            **Non-Greek-Cypriot**[a](#tbl3fna){ref-type="table-fn"} \[*N* (%)\]In situ5(8.5)2(3.1)5(6.6)2(2.6)1(1.5)6(7.4)2(2.4)4(5.5)2(2.8)29(4.5)Invasive54(91.5)63(96.9)71(93.4)75(97.4)64(98.5)75(92.6)81(97.6)69(94.5)69(97.2)621(95.5)                                            **Total** \[N (%)\]In situ38(8.3)21(4.8)53(9.9)44(8.6)40(8.4)49(8.9)49(8.3)42(7.7)59(9.7)395(8.4)Invasive419(91.7)416(95.2)483(90.1)468(91.4)436(91.6)499(91.1)542(91.7)506(92.3)537(90.3)4306(91.6)[^4]Table 4Cancer stage of newly diagnosed breast cancer cases (*N* = 4700) by ethnicity and year of diagnosis (2005--2013).Table 4**Cancer stage200520062007200820092010201120122013TotalGreek-Cypriot** \[*N* (%)\]Distant metastatic16(4.0)17(4.6)25(5.4)23(5.3)18(4.4)17(3.6)19(3.7)15(3.2)9(1.7)159(3.9)In situ33(8.3)19(5.1)48(10.5)42(9.7)39(9.5)43(9.2)47(9.3)38(8.0)57(10.9)366(9.0)Locoregional invasive320(80.4)302(81.2)340(73.9)328(75.4)315(76.6)353(75.6)383(75.4)365(76.8)396(75.6)3102(76.6)Unknown29(7.3)34(9.1)47(10.2)42(9.6)39(9.5)54(11.6)59(11.6)57(12.0)62(11.8)423(10.4)                                            **Non-Greek-Cypriot**[a](#tbl4fna){ref-type="table-fn"} \[*N* (%)\]Distant metastatic1(1.7)3(4.6)4(5.3)5(6.5)3(4.6)6(7.4)2(2.4)6(8.2)2(2.8)32(5.0)In situ5(8.5)2(3.1)5(6.6)2(2.6)1(1.5)6(7.4)2(2.4)4(5.5)2(2.8)29(4.5)Locoregional invasive49(83.0)55(84.6)57(75.0)60(77.9)51(78.5)64(79.0)67(80.7)54(74.0)55(77.5)512(78.8)Unknown4(6.8)5(7.7)10(13.1)10(13.0)10(15.4)5(6.2)12(14.5)9(12.3)12(16.9)77(11.7)                                            **Total** \[*N* (%)\]Distant metastatic17(3.7)20(4.6)29(5.4)28(5.5)21(4.4)23(4.2)21(3.6)21(3.8)11(1.9)191(4.1)In situ38(8.3)21(4.8)53(9.9)44(8.6)40(8.4)49(8.9)49(8.3)42(7.7)59(9.9)395(8.4)Locoregional invasive369(80.8)357(81.7)397(74.1)388(75.7)366(76.9)417(76.1)450(76.1)419(76.5)451(75.8)3614(76.9)Unknown33(7.2)39(8.9)57(10.6)52(10.2)49(10.3)59(10.8)71(12.0)66(12.0)74(12.4)500(10.6)[^5]Table 5Cancer histologic morphological type of newly diagnosed breast cancer cases (*N* = 4700) by ethnicity and year of diagnosis (2005--2013).Table 5**Histologic morphological type200520062007200820092010201120122013TotalGreek-Cypriot** \[*N* (%)\]Adenoid cystic carcinoma0(0.0)0(0.0)1(0.2)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(0.0)Carcinoma with apocrine features0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)2(0.4)0(0.0)0(0.0)1(0.2)3(0.1)Carcinoma with medullary features2(0.5)1(0.3)3(0.7)0(0.0)0(0.0)1(0.2)0(0.0)0(0.0)2(0.4)9(0.2)Cribriform carcinoma0(0.0)0(0.0)2(0.4)0(0.0)0(0.0)1(0.2)0(0.0)0(0.0)2(0.4)5(0.1)Inflammatory carcinoma0(0.0)0(0.0)1(0.2)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(0.0)Invasive carcinoma of no special type291(73.1)256(68.8)338(73.5)354(81.4)328(79.8)353(75.6)406(79.9)381(80.2)416(79.4)3123(77.1)Invasive lobular carcinoma42(10.5)50(13.4)41(8.9)38(8.7)51(12.4)56(12.0)49(9.7)58(12.2)60(11.5)445(11.0)Mesenchymal tumours0(0.0)0(0.0)1(0.2)1(0.2)0(0.0)0(0.0)0(0.0)1(0.2)0(0.0)3(0.1)Metaplastic carcinoma0(0.0)0(0.0)2(0.4)0(0.0)0(0.0)0(0.0)4(0.8)1(0.2)0(0.0)7(0.2)Mucinous carcinoma7(1.8)6(1.6)12(2.6)8(1.8)1(0.2)9(1.9)4(0.8)8(1.7)12(2.3)67(1.7)Paget׳s disease2(0.5)3(0.8)2(0.4)1(0.2)2(0.5)2(0.4)3(0.6)2(0.4)2(0.4)19(0.5)Phyllodes tumour3(0.7)2(0.5)2(0.4)0(0.0)1(0.2)0(0.0)0(0.0)1(0.2)1(0.2)10(0.3)Rare variants42(10.6)48(12.8)47(10.3)28(6.4)22(5.4)37(7.9)37(7.3)21(4.4)24(4.5)306(7.5)Tubular carcinoma9(2.3)6(1.6)8(1.8)5(1.3)6(1.5)6(1.4)5(0.9)2(0.5)4(0.7)51(1.2)                                            **Non-Greek-Cypriot**[a](#tbl5fna){ref-type="table-fn"} \[*N* (%)\]Adenoid cystic carcinoma0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Carcinoma with apocrine features0(0.0)0(0.0)0(0.0)0(0.0)1(1.5)0(0.0)0(0.0)0(0.0)0(0.0)1(0.2)Carcinoma with medullary features0(0.0)0(0.0)1(1.3)0(0.0)1(1.5)0(0.0)0(0.0)0(0.0)0(0.0)2(0.3)Cribriform carcinoma0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Inflammatory carcinoma0(0.0)0(0.0)1(1.3)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(0.2)Invasive carcinoma of no special type50(84.8)57(87.7)59(77.6)60(77.9)51(78.5)69(85.2)72(86.8)63(86.3)56(78.9)537(82.5)Invasive lobular carcinoma6(10.1)4(6.1)5(6.7)10(13.0)7(10.8)6(7.5)4(4.8)5(6.8)8(11.3)55(8.4)Mesenchymal tumours0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Metaplastic carcinoma0(0.0)0(0.0)0(0.0)1(1.3)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(0.2)Mucinous carcinoma1(1.7)0(0.0)1(1.3)0(0.0)2(3.1)1(1.2)0(0.0)1(1.4)3(4.2)9(1.4)Paget׳s disease0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(1.2)1(1.2)1(1.4)0(0.0)3(0.5)Phyllodes tumour0(0.0)0(0.0)1(1.3)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(0.2)Rare variants2(3.4)4(6.2)8(10.5)5(6.5)3(4.6)4(4.9)6(7.2)3(4.1)3(4.2)38(5.8)Tubular carcinoma0(0.0)0(0.0)0(0.0)1(1.3)0(0.0)0(0.0)0(0.0)0(0.0)1(1.4)2(0.3)                                            **Total** \[*N* (%)\]Adenoid cystic carcinoma0(0.0)0(0.0)1(0.2)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(0.0)Carcinoma with apocrine features0(0.0)0(0.0)0(0.0)0(0.0)1(0.2)2(0.4)0(0.0)0(0.0)1(0.2)4(0.1)Carcinoma with medullary features2(0.4)1(0.2)4(0.7)0(0.0)1(0.2)1(0.2)0(0.0)0(0.0)2(0.3)11(0.2)Cribriform carcinoma0(0.0)0(0.0)2(0.4)0(0.0)0(0.0)1(0.2)0(0.0)0(0.0)2(0.3)5(0.1)Inflammatory carcinoma0(0.0)0(0.0)2(0.4)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)2(0.0)Invasive carcinoma of no special type341(74.6)313(71.6)397(74.1)414(80.9)379(79.6)422(77.0)478(80.9)444(81.0)482(79.5)3660(77.9)Invasive lobular carcinoma48(10.5)54(12.3)46(8.5)48(9.3)58(12.2)62(11.2)53(8.9)63(11.4)68(11.3)500(10.7)Mesenchymal tumours0(0.0)0(0.0)1(0.2)1(0.2)0(0.0)0(0.0)0(0.0)1(0.2)0(0.0)3(0.1)Metaplastic carcinoma0(0.0)0(0.0)2(0.4)1(0.2)0(0.0)0(0.0)4(0.7)1(0.2)0(0.0)8(0.2)Mucinous carcinoma8(1.8)6(1.4)13(2.4)8(1.5)3(0.6)10(1.8)4(0.7)9(1.6)15(2.5)76(1.6)Paget׳s disease2(0.4)3(0.7)2(0.4)1(0.2)2(0.4)3(0.6)4(0.7)3(0.6)2(0.3)22(0.5)Phyllodes tumour3(0.7)2(0.5)3(0.6)0(0.0)1(0.2)0(0.0)0(0.0)1(0.2)1(0.2)11(0.2)Rare variants44(9.6)52(11.9)55(10.2)33(6.5)25(5.3)41(7.5)43(7.2)24(4.4)28(4.6)344(7.3)Tubular carcinoma9(2.0)6(1.4)8(1.5)6(1.2)6(1.3)6(1.1)5(0.9)2(0.4)5(0.8)53(1.1)[^6]Table 6Histological classification of breast cancer types and subtypes (based on International Classification of Diseases for Oncology morphological codes, ICD-O-3 [@bib2]).Table 6**Histologic typeICD-O-3 morphology codeCategoriesSubtypes**Adenoid cystic carcinoma8200/3Carcinoma with apocrine features8401/3Carcinoma with medullary featuresAtypical medullary carcinoma8513/3Medullary carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8510/3Cribriform carcinoma8201/3Inflammatory carcinoma8530/3Invasive carcinoma of no special typeDuct carcinoma8500/3Infiltrating duct mixed with other types of carcinoma8523/3Infiltrating ductular carcinoma8521/3Solid carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8230/3Invasive lobular carcinomaInfiltrating lobular mixed with other types of carcinoma8524/3Lobular carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8520/3Mesenchymal tumoursFibrosarcoma, NOS[a](#tbl6fna){ref-type="table-fn"}8810/3Haemangiosarcoma9120/3Liposarcoma, NOS[a](#tbl6fna){ref-type="table-fn"}8850/3Metaplastic carcinomaMetaplastic carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8575/3Signet ring cell carcinoma8490/3Spindle cell carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8032/3Squamous cell carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8070/3Mucinous carcinomaMucin-producing adenocarcinoma8481/3Mucinous adenocarcinoma8480/3Paget׳s diseasePaget disease and infiltrating duct carcinoma of breast8541/3Paget disease and intraductal carcinoma of breast8543/3Paget disease, mammary8540/3Phyllodes tumourPhyllodes tumour, malignant9020/3Rare variantsGranular cell tumour, malignant9580/3Neuroendocrine carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8246/3Papillary adenocarcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8260/3Papillary carcinoma, NOS[a](#tbl6fna){ref-type="table-fn"}8050/3Mixed cell adenocarcinoma8323/3Carcinoma, undifferentiated, NOS[a](#tbl6fna){ref-type="table-fn"}8020/3Tubular carcinomaTubular adenocarcinoma8211/3[^7]Table 7Breast cancer-related deaths (*N* = 930) by gender and year of diagnosis for the period 2005--2013. The numbers of deaths attributable to breast cancer per 1000 deaths are shown in parentheses.Table 7**Gender200520062007200820092010201120122013OverallBreast Cancer Deaths** \[*N* (N per 1000 deaths)\]Female72(27.8)81(32.4)92(35.8)94(38.3)106(44.1)110(46.4)118(45.0)111(41.4)131(54.9)915(40.5)Male0(0.0)2(0.8)1(0.4)3(1.1)3(1.1)1(0.4)2(0.7)3(1.0)0(0.0)15(0.6)Total72(13.3)83(16.2)93(17.3)97(18.7)109(21.0)111(21.8)120(22.3)114(20.1)131(24.8)930(19.5)Table 8Five-year net survival rates of all breast cancer cases by age group.Table 8**Time periodAge groupSurvival analysis method19--2930--3940--4950--5960--6970--7980-OverallNet Survival for 2004--2008 (95% CI**[a](#tbl8fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl8fnb){ref-type="table-fn"}0.85(0.66--1.04)0.88(0.81--0.94)0.91(0.88--0.94)0.87(0.84--0.90)0.84(0.81--0.88)0.69(0.64--0.75)0.36(0.27--0.45)0.82(0.80--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl8fna){ref-type="table-fn"}**) - Period method**[c](#tbl8fnc){ref-type="table-fn"}0.80(0.59--1.00)0.93(0.90--0.97)0.94(0.93--0.96)0.90(0.89--0.92)0.89(0.86--0.91)0.79(0.75--0.82)0.60(0.54--0.66)0.87(0.86--0.88)[^8][^9][^10]Table 9Five-year net survival rates of all breast cancer cases by different cancer grade at diagnosis.Table 9**Time periodCancer GradeSurvival analysis methodI; Well DifferentiatedII; Moderately DifferentiatedIII; Poorly DifferentiatedUndifferentiated/UnknownOverallNet Survival for 2004--2008 (95% CI**[a](#tbl9fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl9fnb){ref-type="table-fn"}0.91(0.86--0.95)0.86(0.83--0.88)0.73(0.69--0.77)0.79(0.74--0.84)0.82(0.80--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl9fna){ref-type="table-fn"}**) - Period method**[c](#tbl9fnc){ref-type="table-fn"}0.92(0.88--0.95)0.89(0.87--0.90)0.84(0.82--0.86)0.88(0.84--0.91)0.87(0.86--0.88)[^11][^12][^13]Table 10Five-year net survival rates of all breast cancer cases by cancer behaviour at diagnosis.Table 10**Time periodCancer BehaviourSurvival analysis methodInvasiveΙn situOverallNet Survival for 2004--2008 (95% CI**[a](#tbl10fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl10fnb){ref-type="table-fn"}0.81(0.79--0.83)0.99(0.96--1.01)0.82(0.80--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl10fna){ref-type="table-fn"}**) - Period method**[c](#tbl10fnc){ref-type="table-fn"}0.86(0.85--0.88)0.98(0.96--1.00)0.87(0.86--0.88)[^14][^15][^16]Table 11Five-year net survival rates of all breast cancer cases by cancer stage at diagnosis.Table 11**Time periodCancer stageSurvival analysis methodDistant metastaticΙn situLocoregional invasiveUnknownOverallNet Survival for 2004--2008 (95% CI**[a](#tbl11fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl11fnb){ref-type="table-fn"}0.34(0.24--0.43)0.99(0.96--1.01)0.85(0.84--0.87)0.56(0.46--0.66)0.82(0.80--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl11fna){ref-type="table-fn"}**) - Period method**[c](#tbl11fnc){ref-type="table-fn"}0.49(0.41--0.58)0.99(0.98--1.00)0.89(0.88--0.90)0.73(0.68--0.79)0.87(0.86--0.88)[^17][^18][^19]Table 12Five-year net survival rates of Greek-Cypriot breast cancer cases by age group.Table 12**Time periodAge groupSurvival analysis method19--2930--3940--4950--5960--6970--7980--OverallNet Survival for 2004--2008 (95% CI**[a](#tbl12fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl12fnb){ref-type="table-fn"}0.83(0.61--1.04)0.86(0.79--0.93)0.90(0.87--0.93)0.88(0.84--0.91)0.85(0.81--0.89)0.69(0.63--0.75)0.37(0.27--0.46)0.81(0.79--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl12fna){ref-type="table-fn"}**) - Period method**[c](#tbl12fnc){ref-type="table-fn"}0.86(0.68--1.03)0.93(0.89--0.97)0.94(0.92--0.96)0.91(0.89--0.93)0.89(0.87--0.91)0.78(0.74--0.81)0.59(0.53--0.66)0.87(0.86--0.88)[^20][^21][^22]Table 13Five-year net survival rates of Greek-Cypriot breast cancer cases by cancer grade at diagnosis.Table 13**Time periodCancer gradeSurvival analysis methodI; Well DifferentiatedII; Moderately DifferentiatedIII; Poorly DifferentiatedUndifferentiated/UnknownOverallNet Survival for 2004--2008 (95% CI**[a](#tbl13fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl13fnb){ref-type="table-fn"}0.91(0.86--0.95)0.85(0.83--0.88)0.73(0.69--0.77)0.79(0.74--0.85)0.81(0.79--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl13fna){ref-type="table-fn"}**) - Period method**[c](#tbl13fnc){ref-type="table-fn"}0.92(0.88--0.95)0.88(0.87--0.90)0.83(0.81--0.86)0.88(0.84--0.91)0.87(0.86--0.88)[^23][^24][^25]Table 14Five-year net survival rates of Greek-Cypriot breast cancer cases by cancer behaviour at diagnosis.Table 14**Time periodCancer behaviourSurvival analysis methodInvasiveIn situOverallNet Survival for 2004--2008 (95% CI**[a](#tbl14fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl14fnb){ref-type="table-fn"}0.80(0.78--0.82)0.98(0.95--1.01)0.81(0.79--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl14fna){ref-type="table-fn"}**) - Period method**[c](#tbl14fnc){ref-type="table-fn"}0.86(0.85--0.87)0.98(0.96--1.00)0.87(0.86--0.88)[^26][^27][^28]Table 15Five-year net survival rates of Greek-Cypriot breast cancer cases by cancer stage at diagnosis.Table 15**Time periodCancer stageSurvival analysis methodDistant metastaticIn situLocoregional invasiveUnknownOverallNet Survival for 2004--2008 (95% CI**[a](#tbl15fna){ref-type="table-fn"}**) - Cohort method**[b](#tbl15fnb){ref-type="table-fn"}0.33(0.24--0.43)0.98(0.95--1.01)0.85(0.83--0.87)0.50(0.39--0.61)0.81(0.79--0.83)**Net Survival for 2009--2013 (95% CI**[a](#tbl15fna){ref-type="table-fn"}**) - Period method**[c](#tbl15fnc){ref-type="table-fn"}0.47(0.39--0.56)0.98(0.96--1.00)0.89(0.88--0.90)0.72(0.66--0.78)0.87(0.86--0.88)[^29][^30][^31]

[Table 1](#t0005){ref-type="table"} shows counts and percentages of newly diagnosed breast cancer cases by gender, age, ethnicity (Greek-Cypriot/Non-Greek-Cypriot/Unknown), marital status at the time of diagnosis (single/married/divorced or separated/widowed/unknown), smoking history at the time of diagnosis (yes/no/unknown), and patients' birthplace (Cyprus districts) as well as the median and the interquartile range (IQR) of patients׳ age. [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"} present counts and percentages of newly diagnosed breast cancer cases by cancer grade (well differentiated/moderately differentiated/poorly differentiated/undifferentiated/ unknown), behaviour (in situ/invasive), stage (distant metastatic/in situ/locoregional invasive/unknown), and histological type at diagnosis (adenoid cystic carcinoma/carcinoma with apocrine features/carcinoma with medullary features/cribriform carcinoma/inflammatory carcinoma/invasive carcinoma of no special type/invasive lobular carcinoma/mesenchymal tumours/metaplastic carcinoma/mucinous carcinoma/Paget׳s disease/phyllodes tumour/rare variants/tubular carcinoma). Cases are also presented by ethnicity (Greek-Cypriot and Non-Greek-Cypriot). Armenians and Maronites belong to the Greek-Cypriot community but represent different ethnic/religious groups and given their small numbers were included along with the European Union (EU) foreigners and the non-EU foreigners in the non-Greek-Cypriot group. The ethnicity group "Unknown" is omitted. Subtypes of breast cancer classified in the categories of histological type used in the analysis are presented in [Table 6](#t0030){ref-type="table"}. [Table 7](#t0035){ref-type="table"} gives breast cancer-related deaths by gender. [Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"} show five-year net survival rates of breast cancer cases, based on cohort and period approaches, for 2004--2008 and 2009--2013, by age group, cancer stage, grade, and behaviour at diagnosis for all recorded cases ([Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}) and for Greek-Cypriots only ([Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"}).

2. Experimental design, materials and methods {#s0010}
=============================================

The data presented in this article were obtained from the Cyprus Cancer Registry and the Causes of Death Registry in the Health Monitoring Unit at the Ministry of Health of the Republic of Cyprus. The Cyprus Cancer Registry collects data from all public and private hospitals as well as from clinics within the Republic of Cyprus [@bib1]. It was established in the context of the Middle East Cancer Consortium (MECC) Cancer Registry Project opened on 1st January 1998 aiming to standardize data items, definitions, and codes in order to ensure reliable comparisons. The reference date of diagnoses that are included in MECC for Cyprus is January 1, 1998. MECC is an intergovernmental organization established in 1996 in Geneva, Switzerland, by an agreement between Cyprus, Egypt, Israel, Jordan, and the Palestinian Authority. The aim of MECC is to raise cancer awareness and reduce the burden of cancer in Middle East [@bib1].

The data in this article refer to the period between 2005 and 2013. The unprocessed data provided by the Health Monitoring Unit at the Ministry of Health were checked for duplicates. Duplicates were deleted from the dataset. Only patients residing in the controlled area by the Republic of Cyprus were included.

Overall, between 2005 and 2013, 4769 newly diagnosed breast cancer cases residing in the Republic of Cyprus were recorded in the Cyprus Cancer Registry. Their demographic characteristics (gender, age, ethnicity, marital status, smoking history, and birthplace) are presented in [Table 1](#t0005){ref-type="table"}. The ethnicity of 69 cases was 'Unknown'. The rest (4700) were classified into Greek-Cypriots and non-Greek Cypriots.

Counts and percentages of 4700 newly diagnosed breast cancer cases of known ethnicity are presented by cancer grade ([Table 2](#t0010){ref-type="table"}), behaviour ([Table 3](#t0015){ref-type="table"}), stage ([Table 4](#t0020){ref-type="table"}), and histological type at diagnosis ([Table 5](#t0025){ref-type="table"}). [Table 6](#t0030){ref-type="table"} shows breast cancer histological categories and their subtypes, which have been presented previously in [Table 5](#t0025){ref-type="table"}, and the respective International Classification of Diseases for Oncology (ICD-O-3) morphological code adopted by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) [@bib2]. [Table 7](#t0035){ref-type="table"} shows breast cancer-related deaths by gender and the number of deaths attributable to breast cancer out of 1000 deaths among women and men, and in both sexes. Information on annual numbers of deaths in Cyprus were obtained from the report on mortality statistics between 2004 and 2014 [@bib3].

[Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"} present 5-year net survival rates for 2004--2008 and 2009--2013. Net survival rates are presented by age group ([Table 8](#t0040){ref-type="table"}), cancer grade ([Table 9](#t0045){ref-type="table"}), behaviour ([Table 10](#t0050){ref-type="table"}), and stage at diagnosis ([Table 11](#t0055){ref-type="table"}). The survival analysis included cases meeting the following criteria: (a) they were followed-up after their diagnosis and (b) their age was known at the time of diagnosis. The most recent entry with an updated cancer status was considered for patients recorded more than once in the registry. Five-year net survival rates were estimated using two different approaches: cohort-based and period [@bib4], [@bib5]. The cohort-based survival analysis involves cases diagnosed in 2004--2008 and their survival has been assessed in the 5 years (2009--2013) following the date of diagnosis. The period approach involves cases diagnosed over the period 2004--2013 but considers their survival experience in recent years i.e. over the period 2009--2013. Therefore, the period method provides more up-to-date estimates and quite closely predicts survival rates that will later be observed for cases diagnosed in 2009--2013. Net survival was estimated using the *stns* command in STATA version 14 [@bib6]. Survival analyses were performed for all cases ([Table 8](#t0040){ref-type="table"}, [Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}, [Table 11](#t0055){ref-type="table"}) and for cases of Greek-Cypriot ethnicity ([Table 12](#t0060){ref-type="table"}, [Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}, [Table 15](#t0075){ref-type="table"}). Background mortality data used for net survival assessment were in the format of age-specific daily death rate for Cyprus and were retrieved by WHO [@bib7]. All data were analyzed using STATA version 14 (StataCorp LP, College Station, Texas, USA).
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[^1]: Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.

[^2]: Birthplace refers to one of the six districts of the Republic of Cyprus.

[^3]: Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.

[^4]: Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.

[^5]: Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.

[^6]: Non-Greek Cypriots include Armenians, Maronites, European Union (EU) foreigners, and non-EU foreigners.

[^7]: NOS stands for Not Otherwise Specified.

[^8]: CI: Confidence Interval.

[^9]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 2296) who were followed up at least five years after their diagnosis.

[^10]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 4324).

[^11]: CI: Confidence Interval.

[^12]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 2296) who were followed up at least five years after their diagnosis.

[^13]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 4324).

[^14]: CI: Confidence Interval.

[^15]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 2296) who were followed up at least five years after their diagnosis.

[^16]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 4324).

[^17]: CI: Confidence Interval.

[^18]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 2296) who were followed up at least five years after their diagnosis.

[^19]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 4324).

[^20]: CI: Confidence Interval.

[^21]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 1982) who were followed up at least five years after their diagnosis.

[^22]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 3735).

[^23]: CI: Confidence Interval.

[^24]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 1982) who were followed up at least five years after their diagnosis.

[^25]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 3735).

[^26]: CI: Confidence Interval.

[^27]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 1982) who were followed up at least five years after their diagnosis.

[^28]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 3735).

[^29]: CI: Confidence Interval.

[^30]: The Cohort method refers to people diagnosed in 2004--2008 (*N* = 1982) who were followed up at least five years after their diagnosis.

[^31]: The Period method refers to survival experiences in 2009--2013 of people diagnosed between 2004--2013 (*N* = 3735).
